Table 2 Base-case results
| Â | Panitumumab | Cetuximab | Difference |
|---|---|---|---|
Life-month gained | 7.84 | 7.92 | Â |
Total QALM | 5.36 | 5.42 | Â |
Total QALY | 0.45 | 0.45 | Â |
Total costs | $66,006 | $71,956 | Â |
Net monetary benefit | $1044 | $ (4193) | Â |
Cost-effectiveness ratio | $147,663 | $159,281 | Â |
INMB | – | – | $5237 |
ICER | – | – | $1,251,775 |